Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.

The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.

The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.

The invention generally provides improved anti-sickled-globin antibodies and fragments thereof. In particular embodiments, the antibody or antigen binding fragment thereof recognizes the s, Glu6Val mutation. In various embodiments, the invention provides a conjugate comprising an anti-s-globin antibody or antigen binding fragment thereof and a detectable label. In particular embodiments, a hybridoma comprising an anti-s-globin antibody contemplated herein is provided.

The invention generally provides improved anti-sickled-globin antibodies and fragments thereof. In particular embodiments, the antibody or antigen binding fragment thereof recognizes the s, Glu6Val mutation. In various embodiments, the invention provides a conjugate comprising an anti-s-globin antibody or antigen binding fragment thereof and a detectable label. In particular embodiments, a hybridoma comprising an anti-s-globin antibody contemplated herein is provided.

The present disclosure relates to anti-human cytomegalovirus (anti-HCMV) antibodies and vaccines as well as diagnostic and therapeutic methods of use.

The present invention relates to methods and tools for discriminating between Vel negative and Vel positive phenotypes. The invention is thus useful for determining Vel blood group status of individuals about to receive blood transfusion.

The present invention relates to methods and tools for discriminating between Vel negative and Vel positive phenotypes. The invention is thus useful for determining Vel blood group status of individuals about to receive blood transfusion.